Back

Aspiration thrombectomy for patients with stroke and late onset to treatment: a subset analysis of the COMPLETE registry

Hassan, A. E.; Fifi, J. T.; Zaidat, O. O.; COMPLETE Study Investigators,

2023-04-27 neurology
10.1101/2023.04.25.23288778 medRxiv
Show abstract

BackgroundThe purpose of this study was to report the safety and performance of aspiration thrombectomy for patients with acute ischemic stroke (AIS) due to anterior circulation large vessel occlusion (LVO) and late onset to treatment. MethodsThis is a retrospective subset analysis of a global prospective multicenter registry (COMPLETE) that enrolled adults with AIS due to LVO and a pre-stroke modified Rankin Scale score (mRS) of 0 or 1 who were treated with aspiration thrombectomy with the Penumbra System. This subset analysis included all patients in the registry who had anterior circulation LVO, an Alberta Stroke Program Early CT Score of at least 6, and late onset to treatment (>6 hours from stroke onset to puncture). ResultsOf the 650 patients in the COMPLETE registry, 167 were included here. The rate of successful revascularization at the end of the procedure was 83.2% (139/167), the rate of good functional outcome (mRS 0-2) at 90 days was 55.4% (87/157), and the all-cause mortality rate at 90 days was 14.4% (24/167). No device-related serious adverse events (SAEs) occurred. Procedure-related SAEs occurred in 9 patients (5.4%) within 24 hours and in 12 patients (7.2%) overall. No significant difference was detected between the outcomes of patients with an onset to puncture time of greater than 6 hours and less than or equal to 12 hours and the outcomes of patients with an onset to puncture time of greater than 12 hours. ConclusionsFor patients with AIS due to anterior circulation LVO and with late onset to treatment, aspiration thrombectomy with the Penumbra System appears to be safe and effective. The rates of good functional outcome and all-cause mortality from this study compared favorably with those rates from the medical management arms of the DAWN and DEFUSE-3 studies. RegistrationURL: https://www.clinicaltrials.gov; Unique identifier: NCT03464565.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.